Oncology

Latest News

money health | Image credit: utah51 - stock.adobe.com
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth

March 14th 2024

In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.

prefilled syringes | Image credit: SOPONE - stock.adobe.com
Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics

March 14th 2024

syringe and vial | Image credit: weyo - stock.adobe.com
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio

March 13th 2024

Patient treated with chemotherapy | Image Credit: NDABCREATIVITY - stock.adobe.com
HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer

March 12th 2024

doctor filling syringe | Image credit: natali_mis - stock.adobe.com
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability

March 11th 2024

Video Series
Video Interviews
Podcasts
CFB podcast banner
CFB podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner
Latest CME Events & Activities

More News

© 2024 MJH Life Sciences

All rights reserved.